{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:52:02Z","timestamp":1793296322292,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011948","name":"Abbott Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.obpill.2025.100186","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T11:45:04Z","timestamp":1749555904000},"page":"100186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study"],"prefix":"10.1016","volume":"15","author":[{"given":"W.","family":"Scott Butsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suela","family":"Sulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-0160","authenticated-orcid":false,"given":"Andrew T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-4775","authenticated-orcid":false,"given":"Kirk W.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5564-0222","authenticated-orcid":false,"given":"Refaat","family":"Hegazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-7821","authenticated-orcid":false,"given":"Thadchaigeni","family":"Panchalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Goates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-9425","authenticated-orcid":false,"given":"Steven B.","family":"Heymsfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2025.100186_bib1","series-title":"National diabetes statistics report website","year":"2023"},{"key":"10.1016\/j.obpill.2025.100186_bib2","series-title":"IDF diabetes atlas","year":"2021"},{"key":"10.1016\/j.obpill.2025.100186_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.obpill.2025.100186_bib4","series-title":"World obesity atlas","year":"2023"},{"key":"10.1016\/j.obpill.2025.100186_bib5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr (Edinb)"},{"key":"10.1016\/j.obpill.2025.100186_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102656","article-title":"Sarcopenia, obesity, and diabetes - the metabolic conundrum trifecta","volume":"16","author":"Jayasinghe","year":"2022","journal-title":"Diabetes Metabol Syndr"},{"key":"10.1016\/j.obpill.2025.100186_bib7","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1038\/s41598-022-09221-w","article-title":"The association between diabetes and hypertension with the number and extent of weight cycles determined from 6 million participants","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.obpill.2025.100186_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s13679-019-00359-9","article-title":"Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives","volume":"8","author":"Koliaki","year":"2019","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.obpill.2025.100186_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1185221","article-title":"Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management","volume":"14","author":"Wei","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2025.100186_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15819","article-title":"The latest evidence and clinical guidelines for use of meal replacements in very-low-calorie diets or low-calorie diets for the treatment of obesity","author":"Edwards-Hampton","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib11","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10.1016\/j.obpill.2025.100186_bib12","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100186_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obesity Pillars"},{"key":"10.1016\/j.obpill.2025.100186_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13663","article-title":"Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists","volume":"25","author":"Goldenberg","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2025.100186_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175634","article-title":"The GLP-1 journey: from discovery science to therapeutic impact","volume":"134","author":"Drucker","year":"2024","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.obpill.2025.100186_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.obpill.2025.100186_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/apt.17856","article-title":"Pharmacologic management of obesity: updates on approved medications, indications and risks","author":"Lupianez-Merly","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.obpill.2025.100186_bib18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1111\/dom.14477","article-title":"Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes","volume":"23","author":"Quast","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib20","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib21","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2022.113967","article-title":"Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity","volume":"257","author":"Nicolau","year":"2022","journal-title":"Physiol Behav"},{"key":"10.1016\/j.obpill.2025.100186_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10.1016\/j.obpill.2025.100186_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/nu13082582","article-title":"Low protein intakes and poor diet quality associate with functional limitations in US adults with diabetes: a 2005-2016 NHANES analysis","volume":"13","author":"Fanelli","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2025.100186_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11695-017-2902-4","article-title":"Prevalence of micronutrient deficiency in patients with morbid obesity before bariatric surgery","volume":"28","author":"Krzizek","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.obpill.2025.100186_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/nu11123046","article-title":"Diet quality and micronutrient intake among long-term weight loss maintainers","volume":"11","author":"Pascual","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2025.100186_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2017-000471","article-title":"Impact of malnutrition on survival and healthcare utilization in Medicare beneficiaries with diabetes: a retrospective cohort analysis","volume":"6","author":"Ahmed","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.obpill.2025.100186_bib28","article-title":"Proportion of caloric restriction-induced weight loss as skeletal muscle","author":"Heymsfield","year":"2023","journal-title":"Obesity (Silver Spring, Md)"},{"key":"10.1016\/j.obpill.2025.100186_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.obpill.2025.100186_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072473","article-title":"Weight loss strategies and the risk of skeletal muscle mass loss","volume":"13","author":"McCarthy","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2025.100186_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.obpill.2025.100186_bib32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2025.100186_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A\u00a0review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.obpill.2025.100186_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib35","doi-asserted-by":"crossref","DOI":"10.2337\/db24-14-PUB","article-title":"14-PUB: the effect of structured intensive lifestyle intervention on muscle mass in patients with type 2 diabetes receiving GLP-1 receptor agonists","volume":"73","author":"Al-Badri","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2025.100186_bib36","first-page":"1288","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation (New York, N Y)"},{"key":"10.1016\/j.obpill.2025.100186_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.obpill.2025.100186_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/nu10040423","article-title":"Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis","volume":"10","author":"Sardeli","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.obpill.2025.100186_bib39","series-title":"Semaglutide interferes with postnatal development of juvenile mice with compromised growth","author":"Joly","year":"2025"},{"key":"10.1016\/j.obpill.2025.100186_bib40","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial","volume":"26","author":"Gabe","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2025.100186_bib41","article-title":"Balancing the risks and benefits of GLP-1 agonists for weight loss","volume":"10","author":"Kumar","year":"2024","journal-title":"Biol Eng Med Sci Rep"},{"key":"10.1016\/j.obpill.2025.100186_bib42","article-title":"Glucagon-like Receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks","volume":"12","author":"Ghusn","year":"2024","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2025.100186_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology (Oxf)"},{"key":"10.1016\/j.obpill.2025.100186_bib44","doi-asserted-by":"crossref","first-page":"R1755","DOI":"10.1152\/ajpregu.00472.2011","article-title":"Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake","volume":"301","author":"McKay","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.obpill.2025.100186_bib45","article-title":"Losing weight plus vitamin B12 following semaglutide administration? A case of false B12 deficiency","author":"Rizos","year":"2024","journal-title":"Adv"},{"key":"10.1016\/j.obpill.2025.100186_bib46","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3945\/an.116.014258","article-title":"Nutritional recommendations for adult bariatric surgery patients: clinical practice","volume":"8","author":"Sherf","year":"2017","journal-title":"Adv Nutr"},{"key":"10.1016\/j.obpill.2025.100186_bib47","series-title":"Anti-obesity medication and the role of lifestyle interventions delivered by RDNs","year":"2024"},{"key":"10.1016\/j.obpill.2025.100186_bib48","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dc24-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2025.100186_bib49","article-title":"Nutrition and physical activity: an obesity medicine association (OMA) clinical practice statement 2022","volume":"1","author":"Alexander","year":"2022","journal-title":"Obes Pillars"},{"key":"10.1016\/j.obpill.2025.100186_bib50","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100186_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.obpill.2025.100186_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1169538","article-title":"Evolution of the diagnosis of malnutrition in adults: a primer for clinicians","volume":"11","author":"Hegazi","year":"2024","journal-title":"Front Nutr"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368125000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:08:53Z","timestamp":1759622933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368125000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"alternative-id":["S2667368125000300"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100186","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2025.100186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100186"}}